Search results for "anticancer"

showing 10 items of 171 documents

Characteristics of advanced cancer patients who were readmitted to an acute palliative/supportive care unit

2017

Objectives: The aim of this study was to assess the characteristics of patients readmitted to an acute supportive/palliative care unit (ASPCU), the reasons for readmission, and the outcome after receiving specialistic assessment and treatment. Methods: A consecutive sample of patients was assessed for a period of 10 months. Epidemiological characteristics, including age, gender, Karnofsky level, diagnosis, caregivers, education, disease awareness, kind of admission, and anticancer treatment in the previous 30 days, were recorded, as well as hospital stay, death, and discharge at home. The principal reasons for admission were recorded. Symptom intensity and opioid doses, expressed as oral …

Malemedicine.medical_specialtyPalliative careCritical CarePain medicineSymptomDiseasePatient Readmission03 medical and health sciences0302 clinical medicineNeoplasmsEpidemiologymedicineHumans030212 general & internal medicineAgedbusiness.industryPalliative CareSymptom burdenAdvanced cancerOpioidOncologyAnticancer treatment030220 oncology & carcinogenesisEmergency medicineNeoplasmFemalebusinessReadmissionSupportive caremedicine.drugHuman
researchProduct

Selective targeting of PARP-1 zinc finger recognition domains with Au(III) organometallics

2018

The binding of Au(iii) complexes to the zinc finger domain of the anticancer drug target PARP-1 was studied using a hyphenated mass spectrometry approach combined with quantum mechanics/molecular mechanics (QM/MM) studies. Competition experiments were carried out, whereby each Au complex was exposed to two types of zinc fingers. Notably, the cyclometallated Au-C^N complex was identified as the most selective candidate to disrupt the PARP-1 zinc finger domain, forming distinct adducts compared to the coordination compound Auphen.

Materials Chemistry2506 Metals and AlloysStereochemistryPoly ADP ribose polymeraseSurfaces Coatings and FilmCeramics and Composite010402 general chemistryMass spectrometry01 natural sciencesMolecular mechanicsCatalysisCoordination complexAdductCatalysiMaterials Chemistrychemistry.chemical_classificationZinc finger010405 organic chemistryElectronic Optical and Magnetic MaterialChemistry (all)Metals and AlloysGeneral ChemistryAnticancer drug0104 chemical sciencesSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialschemistrySettore CHIM/03 - Chimica Generale E InorganicaCeramics and Composites2506
researchProduct

Ultralow-intensity near-infrared light induces drug delivery by upconverting nanoparticles

2014

Mesoporous silica coated upconverting nanoparticles are loaded with the anticancer drug doxorubicin and grafted with ruthenium complexes as photoactive molecular valves. Drug release was triggered by 974 nm light with 0.35 W cm(-2). Such low light intensity minimized overheating problems and prevented photodamage to biological samples.

Materials scienceNear infrared lightMetals and Alloyschemistry.chemical_elementNanotechnologyGeneral ChemistryMesoporous silicaPhotochemistryAnticancer drugCatalysisSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsRutheniumLight intensitychemistryDrug deliveryMaterials ChemistryCeramics and CompositesUpconverting nanoparticlesOverheating (electricity)Chemical Communications
researchProduct

Fluorescence spectroscopy for estimation of anticancer drug sonodestruction in vitro

2013

The effect of ultrasound exposure on bleomycin fluorescence and pharmacological properties is studied. Bleomycin was treated by ultrasound for 7 min. Bleomycin fluorescence was measured during ultrasound exposure by means of fiber-optic spectrometry. Cell colony test was used to evaluate blemycin cytotoxity before and after ultrasound exposure.

Materials sciencebusiness.industryUltrasoundUltrasound exposurerespiratory systemPharmacologyBleomycinFluorescenceAnticancer drugIn vitroFluorescence spectroscopyrespiratory tract diseasescarbohydrates (lipids)chemistry.chemical_compoundNuclear magnetic resonancechemistrybusinessSonoporationSPIE Proceedings
researchProduct

Metal drugs and the anticancer immune response

2018

The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting…

Metal Drugs Immune Response Anticancer cisplatinanimal diseasesmedicine.medical_treatmentEvasion (network security)chemical and pharmacologic phenomenaAntineoplastic Agents010402 general chemistry01 natural sciencesMalignant transformationImmune systemImmunityCoordination ComplexesNeoplasmsmedicineHumansLymphocytesTumor microenvironment010405 organic chemistryChemistryGeneral ChemistryImmunotherapybiochemical phenomena metabolism and nutritionAcquired immune systemImmunity Innate0104 chemical sciencesGastrointestinal MicrobiomeMetalsSettore CHIM/03 - Chimica Generale E InorganicaCancer cellbacteriaNanoparticlesImmunotherapyNeuroscience
researchProduct

Multinuclear Cytotoxic Metallodrugs: Physicochemical Characterization and Biological Properties of Novel Heteronuclear Gold-Titanium Complexes

2011

An unprecedented series of titanocene-gold bi- and trimetallic complexes of the general formula [[(η(5)-C(5)H(5))(μ-η(5):κ(1)-C(5)H(4)(CH(2))(n)PPh(2))TiCl(2)](m)AuCl(x)](q+) (n = 0, 2, or 4; m = 1, x = 1, q = 0 or m = 2, x = 0, q = 1) have been prepared and characterized spectroscopically. The luminescence spectroscopy and photophysics of one of the compounds, [[(η(5)-C(5)H(5))(μ-η(5):κ(1)-C(5)H(4)PPh(2))TiCl(2)](2)Au]PF(6), have been investigated in 2MeTHF solution and in the solid state at 77 and 298 K. Evidence for interfragment interactions based on the comparison of electronic band positions and emission lifetimes, namely, triplet energy transfer (ET) from the Au- to the Ti-containing…

Models MolecularSpectrometry Mass Electrospray IonizationLuminescenceMagnetic Resonance SpectroscopyTransfer Excited-StatesCell SurvivalStereochemistryAntineoplastic AgentsCharge-TransferUnsaturated-HydrocarbonsCrystallography X-RayElectronic-StructuresInorganic ChemistryStructure-Activity Relationshipchemistry.chemical_compoundCell Line TumorOrganometallic CompoundsHumansPhysical and Theoretical ChemistrySpectroscopyGroup 2 organometallic chemistryTitaniumArene-Ruthenium ComplexesX-rayTitanocene dichlorideNuclear magnetic resonance spectroscopyChromophoreTitanocene DichlorideCrystallographychemistryHeteronuclear moleculeAnticancer AgentsSpectrophotometry UltravioletGoldLuminescenceGold(Iii) CompoundsPhotophysical Properties
researchProduct

On the Mechanism of Gold/NHC Compounds Binding to DNA G-Quadruplexes: Combined Metadynamics and Biophysical Methods

2018

The binding modes and free-energy landscape of two AuI /N-heterocyclic carbene complexes interacting with G-quadruplexes, namely a human telomeric (hTelo) and a promoter sequence (C-KIT1), are studied here for the first time by metadynamics. The theoretical results are validated by FRET DNA melting assays and provide an accurate estimate of the absolute gold complex/DNA binding free energy. This advanced in silico approach is valuable to achieve rational drug design of selective G4 binders.

Molecular Structure010405 organic chemistryIn silicoMetadynamicsDrug designSequence (biology)General MedicineDNAGeneral Chemistryanticancer010402 general chemistryG-quadruplex01 natural sciencesCombinatorial chemistryCatalysis0104 chemical sciencesG-Quadruplexeschemistry.chemical_compoundNucleic acid thermodynamicsFörster resonance energy transferchemistryFluorescence Resonance Energy TransferN-heterocyclic carbenesGoldDNAAngewandte Chemie International Edition
researchProduct

Identification of 2-(thiophen-2-yl)acetic Acid-Based Lead Compound for mPGES-1 Inhibition.

2021

We report the implementation of our in silico/synthesis pipeline by targeting the glutathione-dependent enzyme mPGES-1, a valuable macromolecular target in both cancer therapy and inflammation therapy. Specifically, by using a virtual fragment screening approach of aromatic bromides, straightforwardly modifiable by the Suzuki-Miyaura reaction, we identified 3-phenylpropanoic acid and 2-(thiophen-2-yl)acetic acid to be suitable chemical platforms to develop tighter mPGES-1 inhibitors. Among these, compounds 1c and 2c showed selective inhibitory activity against mPGES-1 in the low micromolar range in accordance with molecular modeling calculations. Moreover, 1c and 2c exhibited interesting IC…

Molecular modelIn silicoanti-inflammatory drugsanti-inflammatory drugs; anticancer agents; fragment-based approach; mPGES-1 inhibitors; Suzuki-Miyaura cross-coupling01 natural sciences03 medical and health sciencesAcetic acidchemistry.chemical_compoundanticancer agentsQD1-999Suzuki-Miyaura cross-coupling030304 developmental biologyOriginal ResearchA549 cellchemistry.chemical_classification0303 health sciences010405 organic chemistryfragment-based approachmPGES-1 inhibitorsGeneral ChemistryCombinatorial chemistry0104 chemical sciencesChemistryEnzymechemistryApoptosisLead compoundMacromoleculeFrontiers in chemistry
researchProduct

Conjugados poliméricos y su utilización como nanomedicinas anticancerígenas

2009

Independientemente del descubrimiento de nuevos fármacos para dianas farmacológicas bien establecidas, el compromiso de la ciencia con la sociedad demanda del desarrollo de análogos macromoleculares que mejoren las posibilidades terapéuticas de los fármacos existentes aportando una mayor actividad biológica y una mayor especificidad. Se postula, cada vez con más fuerza, que la aplicación de la nanotecnología a la medicina es la clave para conseguir las mejoras necesarias tanto en diagnosis como en terapia anticancerígeno [1]. Para poder distinguirlos de otros productos biotecnológicos como proteínas y anticuerpos, los nanofármacos han sido definidos como “... sistemas complejos de escala na…

NanomedicinasConjugados poliméricos:CIENCIAS MÉDICAS ::Farmacología [UNESCO]AnticancerígenosUNESCO::CIENCIAS MÉDICAS ::FarmacologíaConjugados poliméricos; Nanomedicinas; Anticancerígenos
researchProduct

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions

2018

IF 0.795 (2017); International audience; The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocr…

Oncologymedicine.medical_specialtyConsensusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic Agents030209 endocrinology & metabolism[SDV.CAN]Life Sciences [q-bio]/CancerEndocrine System Diseases03 medical and health sciences0302 clinical medicineEndocrinologyDysthyroidismNeoplasmsInternal medicineAnimalsHumansMedicineEndocrine systemHypophysitisAdverse effectMTOR inhibitorsTyrosine kinase inhibitorsAdrenal failurebusiness.industryDiabetesGeneral MedicineImmunotherapy[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDiscovery and development of mTOR inhibitors3. Good healthDyslipidemiaAnticancer treatment030220 oncology & carcinogenesisAdrenal failureImmunotherapybusiness
researchProduct